Doseloop Beta

Pantoprazole

medication Under review

A proton pump inhibitor (PPI) used to treat conditions involving excessive stomach acid, such as GERD.

Research summary

AI-Generated Content: This summary was created by AI and may contain errors. Always verify with peer-reviewed sources.

Pantoprazole has been evaluated in over one hundred clinical trials, including randomized controlled trials, cohort studies, and long‑term extension studies in adults. The overall research consensus is that pantoprazole provides effective and durable gastric acid suppression, leading to high rates of healing in erosive esophagitis and substantial improvement in GERD symptoms and patient‑reported quality of life in otherwise healthy subjects. Comparative studies indicate that pantoprazole is at least as effective as other proton pump inhibitors and generally more effective than histamine‑2 receptor antagonists for both acute treatment and maintenance therapy of GERD. Its tolerability profile in healthy adults is favorable, with most adverse events being mild and transient gastrointestinal or headache‑type symptoms. Long‑term observational data and regulatory reviews highlight potential risks associated with chronic PPI therapy, including nutrient malabsorption, alterations in bone health, and increased susceptibility to certain infections, but these are typically infrequent and more strongly associated with prolonged high‑dose use.

Reported Benefits

Reported Side Effects

Related health conditions

Research showing how this habit affects specific health conditions. Always consult healthcare professionals.

May Help With

Research (4 studies)

RCT

Efficacy of S-pantoprazole 10 mg in the symptom control of non-erosive gastroesophageal reflux disease

Journal of Neurogastroenterology and Motility • 2015 • n=209

Kim JH, Park H, Kim JW, Kim HS, et al.

Cohort study

Long-term treatment with pantoprazole for gastroesophageal reflux disease: effects on serum gastrin and safety parameters

PROTONIX (pantoprazole sodium) Delayed-Release Tablets NDA Label Clinical Study Summary • 2007 • n=178

Katz PO, Gerson LB, et al.

RCT

Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.

American Journal of Gastroenterology • 2001 • n=209

Robinson M, Sahba B, Avgerinos A, Lernmark M, Miner P Jr

RCT

Pantoprazole for erosive esophagitis: comparison with ranitidine in a randomized double-blind trial

American Journal of Gastroenterology • 1998 • n=295

Fennerty MB, Castell DO, et al.

Community updates

No updates yet for this supplement.

Be the first to share your experience!

At a glance

Users tracking 0
Linked studies 4
Researched benefits 3
Side effects noted 4